Suchergebnisse - "Kirsebom, Freja Cordelia Møller"

PubPharm (5)

1

Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in England

enthalten in: EClinicalMedicine | 2024

von Kirsebom, F. | Andrews, N. | Stowe, J. | +3

2

Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. and XBB.1.5 in England

enthalten in: The Lancet regional health. Europe | 2023

von Kirsebom, F. | Harman, K. | Lunt, R. | +10

3

Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England : a test-negative case-control study

enthalten in: The Lancet. Infectious diseases | 2023

von Kirsebom, F. | Andrews, N. | Stowe, J. | +2

CommentIn: Lancet Infect Dis. 2023 Nov;23(11):1208-1209. - PMID 37453442

4

Effectiveness of the adjuvanted Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation amongst adults aged 75 years and older in England, estimated using a test-negative case control study design

enthalten in: bioRxiv.org | 2023

von Kirsebom, F. | Andrews, N. | Stowe, J. | +3

5

Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England

enthalten in: Nature communications | 2022

von Kirsebom, F. | Andrews, N. | Sachdeva, R. | +3

1
[1]